Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 442

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 442
---
     |   |   5,884 |     |   |  12,285 |
| Other                 |     |   |   5,563 |     |   |  13,298 |
| Total                 |     | $ | 231,858 |     | $ | 148,648 |

NOTE 8 — CONVERTIBLE NOTES PAYABLE

Founders

Convertible notes payable consist of the following:

|                                 |     |   | May 31, 
    2025 |     |   | May 31, 
    2024 |
|:--------------------------------|:----|:--|--------:|:----|:--|--------:|
| Executive director              |     | $ | 872,245 |     | $ | 536,861 |
| Former Chief Scientific Officer |     |   |  85,417 |     |   |  77,321 |
| Total                           |     | $ | 957,662 |     | $ | 614,182 |

In the year ended May 31, 2024, the Company amended its outstanding convertible note (“Note”) to its executive director to reflect additional borrowings of $200,000 during the year and interest accrued to the date of the amended note. In the year ended May 31, 2025, the Company amended its outstanding convertible note (“Note”) to its executive director to reflect additional borrowings of $300,000 during the year and interest accrued to the date of the amended note. The Company estimates that the nominal interest rate on the Note is less than rates that may be obtained from third parties. The Company recorded discounts of $35,063 on the additional borrowing at an estimated effective rate of 10%, as an addition to paid-in capital. Other terms and conditions of the Note were not affected. The notes are payable in full on December 31, 2026.

<div align='center'>F-15

DIAMIR BIOSCIENCES CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

NOTE 8 — CONVERTIBLE NOTES PAYABLE(cont.)

No payments of principal or interest on the notes are required prior to maturity. The notes call for interest at 4% per annum, compounded monthly and are convertible, at the option of the holder, upon the Company’s next equity financing involving the Company’s sale of its equity securities to third party investors. Upon any conversion, all unpaid principal and accrued unpaid interest on the Notes will be exchanged for